MicroRNAs: Role and therapeutic targets in viral hepatitis Meike H van der Ree

Antiviral Therapy

Volumn 19, Issue 6, 2014, Pages 533-541

  Van Ree, Meike H Der ^a   De Bruijne, Joep ^a   Kootstra, Neeltje A ^a   Jansen, Peter L M ^a   Reesink, Hendrik W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTAGOMIR; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; BOCEPREVIR; MICRORNA; MICRORNA 101; MICRORNA 122; MICRORNA 125A 5P; MICRORNA 141; MICRORNA 196; MICRORNA 199A 3P; MICRORNA 21; MICRORNA 210; MICRORNA 27A; MICRORNA 27B; MICRORNA 29; MICRORNA 372; MICRORNA 373; MICRORNA 99A; MIRAVIRSEN; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; OLIGONUCLEOTIDE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PEGINTERFERON; PLACEBO; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; DOSE RESPONSE; DRUG RESPONSE; FATTY LIVER; GENE INACTIVATION; GENE SILENCING; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER METABOLISM; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS HEPATITIS; VIRUS INHIBITION; VIRUS REPLICATION; CLASSIFICATION; GENE THERAPY; GENETICS; HEPATITIS VIRUS; HEPATITIS, VIRAL, HUMAN; METABOLISM; VIROLOGY;

GENETIC THERAPY; HEPATITIS VIRUSES; HEPATITIS, VIRAL, HUMAN; HUMANS; MICRORNAS;

EID: 84920136959     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2766     Document Type: Review

References (111)

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin- 4 encodes small RNAs with antisense complementarity to lin- 14 . Cell 1993; 75: 843-854.
2. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403:901-906.
3. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294: 853-858.
4. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001; 294:858-862.
5. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001; 294:862-864.
6. miRBase. (Accessed 8 January 2014.) Available from http:// www.mirbase.org/
7. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141:672-675.
8. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011; 80:193-208.
9. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105:10513-10518.
10. Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671-678.
11. Zhang H, Li Q-Y, Guo Z-Z, et al. Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. World J Gastroenterol 2012; 18:5188-5196.
12. van der Meer AJ, Farid WRR, Sonneveld MJ, et al. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat 2013; 20:158-166.
13. Marquez RT, Bandyopadhyay S, Wendlandt EB, et al . Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010; 90:1727-1736.
14. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1:106-113.
15. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12:735-739.
16. Esau C, Davis S, Murray S, Yu X. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3:87-98.
17. Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438:685-689.
18. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liverspecific microRNA. Science 2005; 309:1577-1581.
19. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al . Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.
20. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009; 285:116-126.
21. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9:775-789.
22. Pandey AK, Agarwal P, Kaur K, Datta M. MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem 2009; 23:221-232.
23. Cai B, Pan Z, Lu Y. The roles of microRNAs in heart diseases: a novel important regulator. Curr Med Chem 2010; 17:407-411.
24. Liang M, Liu Y, Mladinov D, et al. MicroRNA: a new frontier in kidney and blood pressure research. Am J Physiol Renal Physiol 2009; 297:F553-F558.
25. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
26. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23:4051-4060.
27. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006; 13:1097-1101.
28. Han J, Lee Y, Yeom K-H, Kim Y-K, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004; 18:3016-3027.
29. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425:415-419.
30. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004; 10:185-191.
31. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404:293-296.
32. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-233.
33. Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011; 3:83-92.
34. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007; 23:175-205.
35. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433:769-773.
36. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20.
37. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92-105.
38. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75:855-862.
39. Meijer HA, Kong YW, Lu WT, et al. Translational repression and eIF4A2 activity are critical for microRNA-mediated gene regulation. Science 2013; 340:82-85.
40. Djuranovic S, Nahvi A, Green R. miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science 2012; 336:237-240.
41. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10:553-562.
42. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-1342.
43. Lauer GM, Walker BD, Hepatitis C. Virus infection. N Engl J Med 2001; 345:41-52.
44. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
45. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
46. Flisiak R, Jaroszewicz J, Flisiak I, Łapiński T. Update on alisporivir in treatment of viral hepatitis C. Expert Opin Investig Drugs 2012; 21:375-382.
47. Jopling CL. Regulation of hepatitis C virus by microRNA-122. Biochem Soc Trans 2008; 36:1220-1223.
48. Li Y-P, Gottwein JM, Scheel TK, Jensen TB, Bukh J. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proc Natl Acad Sci U S A 2011; 108:4991-4996.
49. Machlin ES, Sarnow P, Sagan SM. Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A 2011; 108:3193-3198.
50. Jopling CL, Schütz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 2008; 4:77-85.
51. Shimakami T, Yamane D, Jangra RK, et al. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A 2012; 109:941-946.
52. Henke JI, Goergen D, Zheng J, et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008; 27:3300-3310.
53. Narbus CM, Israelow B, Sourisseau M, et al. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol 2011; 85:12087-12092.
54. Fukuhara T, Kambara H, Shiokawa M, et al. Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus. J Virol 2012; 86:7918-7933.
55. Janssen HLA, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368:1685-1694.
56. Conrad KD, Niepmann M. The role of microRNAs in hepatitis C virus RNA replication. Arch Virol 2014; 159:849-862.
57. Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009; 50:453-460.
58. Cheng J-C, Yeh Y-J, Tseng C-P, et al. Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci 2012; 69:2621-2633.
59. Scagnolari C, Zingariello P, Vecchiet J, et al. Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha. Virol J 2010; 7:311.
60. Pedersen IM, Cheng G, Wieland S, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449:919-922.
61. Liu Z, Tian Y, Machida K, et al. Transient activation of the PI3K-AKT pathway by hepatitis C virus to enhance viral entry. J Biol Chem 2012; 287:41922-41930.
62. Ishida H, Tatsumi T, Hosui A, et al. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun 2011; 412:92-97.
63. Singaravelu R, Chen R, Lyn RK, et al. Hepatitis C virus induced up-regulation of microRNA-27: A novel mechanism for hepatic steatosis. Hepatology 2014; 59:98-108.
64. Shirasaki T, Honda M, Shimakami T, et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol 2013; 87:5270-5286.
65. McFarland AP, Horner SM, Jarret A, et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014; 15:72-79.
66. Bihrer V, Friedrich-Rust M, Kronenberger B, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011; 106:1663-1669.
67. Morita K, Taketomi A, Shirabe K, et al. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 2011; 31:474-484.
68. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 2011; 6:e23937.
69. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009; 15:31-33.
70. Murakami Y, Tanaka M, Toyoda H, et al. Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics 2010; 3:48.
71. Waidmann O, Bihrer V, Kronenberger B, Zeuzem S, Piiper A, Forestier N. Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection. Dig Liver Dis 2012; 44:438-441.
72. Bala S, Tilahun Y, Taha O. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med 2012; 10:151.
73. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486-1500.
74. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-168.
75. Chen Y, Shen A, Rider PJ, et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 2011; 25:4511-4521.
76. Qiu L, Fan H, Jin W, et al. miR-122-induced downregulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 2010; 398:771-777.
77. Wang S, Qiu L, Yan X, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1)-modulated P53 activity. Hepatology 2012; 55:730-741.
78. Hao J, Jin W, Li X, et al. Inhibition of alpha interferon (IFN-a)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-a. J Virol 2013; 87:137-147.
79. Zhang GL, Li YX, Zheng SQ, Liu M, Li X, Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res 2010; 88: 169-175.
80. Coppola N, Potenza N, Pisaturo M, et al. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS ONE 2013; 8:e65336.
81. Guo H, Liu H, Mitchelson K, et al . MicroRNAs-372/373 promote the expression of hepatitis B virus through the targeting of nuclear factor I/B. Hepatology 2011; 54:808-819.
82. Jin J, Tang S, Xia L, Du R, Xie H, Song J, et al. MicroRNA-501 promotes HBV replication by targeting HBXIP. Biochem Biophys Res Commun 2013; 430:1228-1233.
83. Hu W, Wang X, Ding X, et al. MicroRNA-141 represses HBV replication by targeting PPARA. PLoS ONE 2012; 7:e34165.
84. Su C, Hou Z, Zhang C, Tian Z, Zhang J. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol J 2011; 8:354.
85. Wei X, Xiang T, Ren G, et al. MiR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal 2013; 25:439-446.
86. Arataki K, Hayes CN, Akamatsu S, et al. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B. J Med Virol 2013; 85:789-798.
87. Waidmann O, Bihrer V, Pleli T, et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 2012; 19:e58-e65.
88. Hayes CN, Akamatsu S, Tsuge M, et al. Hepatitis B virusspecific miRNAs and argonaute2 play a role in the viral life cycle. PLoS ONE 2012; 7:e47490.
89. Zhang X, Chen C, Wu M, et al. Plasma microRNA profile as a predictor of early virological response to interferon treatment in chronic hepatitis B patients. Antivir Ther 2012; 17:1243-1253.
90. Elmén J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNAantimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008; 36:1153-1162.
91. Elmén J, Lindow M, Schütz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896-899.
92. Hsu SH, Wang B, Kota J, et al. Essential metabolic, antiinflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012; 122:2871-2883.
93. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011; 70 Suppl 1:i104-i108.
94. Tsai W-C, Hsu S-D, Hsu C-S, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122:2884-2897.
95. Noetel A, Kwiecinski M, Elfimova N, Huang J, Odenthal M. microRNA are central players in anti- and profibrotic gene regulation during liver fibrosis. Front Physiol 2012; 3:49.
96. He Y, Huang C, Zhang S, Sun X, Long X, Li J. The potential of microRNAs in liver fibrosis. Cell Signal 2012; 24:2268-2272.
97. Trebicka J, Anadol E, Elfimova N, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 2013; 58:234-239.
98. Roderburg C, Urban G-W, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011; 53:209-218.
99. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371:838-851.
100. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9:191-211.
101. Borel F, Konstantinova P, Jansen PLM. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56:1371-1383.
102. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25:2537-2545.
103. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28:3526-3536.
104. Köberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013; 49:3442-3449.
105. Bai S, Nasser MW, Wang B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009; 284:32015-32027.
106. Gordon EM, Liu PX, Chen ZH, et al. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res 2000; 60:3343-3347.
107. Fornari F, Gramantieri L, Giovannini C, et al. MiR-122/ cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69:5761-5767.
108. Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67:6092-6099.
109. Tsai W-C, Hsu PW-C, Lai T-C, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009; 49:1571-1582.
110. Lin CJ-F Gong H.-Y. Tseng H.-C. Wang W.-L. Wu J.-L. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines Biochem Biophys Res Commun 2008 375 315-320
111. Lin CJ-F, Gong H-Y, Tseng H-C, Wang W-L, Wu J-L. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2008; 375:315-320. 111. Zeng C, Wang R, Li D, et al. A novel GSK-3 beta-C/ EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 2010; 52:1702-1712.